ESR1 and ductal breast carcinoma in situ: Clinical trials such as the NSABP-B24 have shown a significant reduction of subsequent breast cancer recurrence in a cohort of women with ER+ DCIS treated with Tamoxifen [25, 26, 67], whereas patients with ER-DCIS derived no benefit.